This content is from: European Union

In depth: Why HGS ruling will benefit biotech investment

Yesterday’s Supreme Court decision in HGS v Eli Lilly gives applicants more certainty by bringing UK law on industrial applicability into line with that applied in the EPO

Get Free Access to read more …

To read the full article, activate your free trial.

Get Free Access
  • Unlimited articles for one week
  • No commitments; no payment details required
  • Featuring IP strategy, copyright, patents, trademark and more!

Are you a Managing IP subscriber? Simply login here.

Related